TH71270B - อนุพันธ์เมทาสทินและการใช้ของสารเหล่านั้น - Google Patents
อนุพันธ์เมทาสทินและการใช้ของสารเหล่านั้นInfo
- Publication number
- TH71270B TH71270B TH601006440A TH0601006440A TH71270B TH 71270 B TH71270 B TH 71270B TH 601006440 A TH601006440 A TH 601006440A TH 0601006440 A TH0601006440 A TH 0601006440A TH 71270 B TH71270 B TH 71270B
- Authority
- TH
- Thailand
- Prior art keywords
- trp
- phe
- arg
- tyr
- leu
- Prior art date
Links
- -1 amino metastin Chemical compound 0.000 claims abstract 72
- 206010028980 Neoplasm Diseases 0.000 claims abstract 13
- 201000011510 cancer Diseases 0.000 claims abstract 11
- 229940079593 drug Drugs 0.000 claims abstract 11
- 239000003814 drug Substances 0.000 claims abstract 10
- 238000004519 manufacturing process Methods 0.000 claims abstract 10
- 239000002253 acid Substances 0.000 claims abstract 8
- 230000028327 secretion Effects 0.000 claims abstract 8
- 239000000470 constituent Substances 0.000 claims abstract 7
- 239000003163 gonadal steroid hormone Substances 0.000 claims abstract 7
- KAHDONZOCXSKII-NJVVDGNHSA-N kisspeptin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)O)C1=CN=CN1 KAHDONZOCXSKII-NJVVDGNHSA-N 0.000 claims abstract 4
- 150000001413 amino acids Chemical class 0.000 claims abstract 3
- 230000000694 effects Effects 0.000 claims abstract 3
- 150000001875 compounds Chemical class 0.000 claims 244
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 45
- 239000000126 substance Substances 0.000 claims 43
- 150000003839 salts Chemical class 0.000 claims 38
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 18
- 108010011485 Aspartame Proteins 0.000 claims 11
- 229960003438 aspartame Drugs 0.000 claims 11
- 235000010357 aspartame Nutrition 0.000 claims 11
- 239000000605 aspartame Substances 0.000 claims 11
- 239000005556 hormone Substances 0.000 claims 10
- 229940088597 hormone Drugs 0.000 claims 10
- 230000002265 prevention Effects 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims 8
- OWIUPIRUAQMTTK-UHFFFAOYSA-N carbazic acid Chemical compound NNC(O)=O OWIUPIRUAQMTTK-UHFFFAOYSA-N 0.000 claims 8
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 8
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims 7
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 7
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 7
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 claims 6
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims 6
- 125000002849 D-tyrosine group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 claims 6
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 claims 6
- 230000002159 abnormal effect Effects 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- PECYZEOJVXMISF-UWTATZPHSA-N 3-amino-D-alanine Chemical compound NC[C@@H](N)C(O)=O PECYZEOJVXMISF-UWTATZPHSA-N 0.000 claims 5
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 claims 5
- 230000001419 dependent effect Effects 0.000 claims 5
- 210000004907 gland Anatomy 0.000 claims 5
- 125000000350 glycoloyl group Chemical group O=C([*])C([H])([H])O[H] 0.000 claims 5
- RWLSBXBFZHDHHX-VIFPVBQESA-N (2s)-2-(naphthalen-2-ylamino)propanoic acid Chemical compound C1=CC=CC2=CC(N[C@@H](C)C(O)=O)=CC=C21 RWLSBXBFZHDHHX-VIFPVBQESA-N 0.000 claims 4
- DCXYFEDJOCDNAF-UWTATZPHSA-N D-Asparagine Chemical compound OC(=O)[C@H](N)CC(N)=O DCXYFEDJOCDNAF-UWTATZPHSA-N 0.000 claims 4
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims 4
- ZDXPYRJPNDTMRX-GSVOUGTGSA-N D-glutamine Chemical compound OC(=O)[C@H](N)CCC(N)=O ZDXPYRJPNDTMRX-GSVOUGTGSA-N 0.000 claims 4
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 claims 4
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 claims 4
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims 4
- AYFVYJQAPQTCCC-STHAYSLISA-N D-threonine Chemical compound C[C@H](O)[C@@H](N)C(O)=O AYFVYJQAPQTCCC-STHAYSLISA-N 0.000 claims 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 4
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims 4
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 4
- 235000004279 alanine Nutrition 0.000 claims 4
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 229940127557 pharmaceutical product Drugs 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 235000019260 propionic acid Nutrition 0.000 claims 4
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims 4
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 4
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 4
- XWHHYOYVRVGJJY-QMMMGPOBSA-N 4-fluoro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(F)C=C1 XWHHYOYVRVGJJY-QMMMGPOBSA-N 0.000 claims 3
- 206010000234 Abortion spontaneous Diseases 0.000 claims 3
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N Alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims 3
- 206010003805 Autism Diseases 0.000 claims 3
- 208000020706 Autistic disease Diseases 0.000 claims 3
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims 3
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 claims 3
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims 3
- NBQCNZYJJMBDKY-UHFFFAOYSA-N Terbacil Chemical compound CC=1NC(=O)N(C(C)(C)C)C(=O)C=1Cl NBQCNZYJJMBDKY-UHFFFAOYSA-N 0.000 claims 3
- 206010046798 Uterine leiomyoma Diseases 0.000 claims 3
- 235000001014 amino acid Nutrition 0.000 claims 3
- 230000006735 deficit Effects 0.000 claims 3
- 230000035558 fertility Effects 0.000 claims 3
- 230000001605 fetal effect Effects 0.000 claims 3
- 125000003651 hexanedioyl group Chemical group C(CCCCC(=O)*)(=O)* 0.000 claims 3
- 230000006698 induction Effects 0.000 claims 3
- 230000036512 infertility Effects 0.000 claims 3
- 230000037356 lipid metabolism Effects 0.000 claims 3
- 208000015994 miscarriage Diseases 0.000 claims 3
- 201000008814 placenta cancer Diseases 0.000 claims 3
- 230000002028 premature Effects 0.000 claims 3
- 239000006041 probiotic Substances 0.000 claims 3
- 230000000529 probiotic effect Effects 0.000 claims 3
- 235000018291 probiotics Nutrition 0.000 claims 3
- 208000000995 spontaneous abortion Diseases 0.000 claims 3
- 230000002269 spontaneous effect Effects 0.000 claims 3
- 230000004936 stimulating effect Effects 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- SCIFESDRCALIIM-VIFPVBQESA-N N-methyl-L-phenylalanine Chemical compound C[NH2+][C@H](C([O-])=O)CC1=CC=CC=C1 SCIFESDRCALIIM-VIFPVBQESA-N 0.000 claims 2
- YWCASUPWYFFUHE-UHFFFAOYSA-N bis(3-methylsulfonyloxypropyl)azanium;chloride Chemical compound [Cl-].CS(=O)(=O)OCCC[NH2+]CCCOS(C)(=O)=O YWCASUPWYFFUHE-UHFFFAOYSA-N 0.000 claims 2
- 125000001589 carboacyl group Chemical group 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 201000010260 leiomyoma Diseases 0.000 claims 2
- 230000004060 metabolic process Effects 0.000 claims 2
- 230000016087 ovulation Effects 0.000 claims 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 2
- 210000002826 placenta Anatomy 0.000 claims 2
- LGUSYNSKJNOQKY-UHFFFAOYSA-N 2,4-diaminobutan-1-ol Chemical compound NCCC(N)CO LGUSYNSKJNOQKY-UHFFFAOYSA-N 0.000 claims 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- 102000002322 Egg Proteins Human genes 0.000 claims 1
- 108010000912 Egg Proteins Proteins 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 206010027145 Melanocytic naevus Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- NSTPXGARCQOSAU-VIFPVBQESA-N N-formyl-L-phenylalanine Chemical compound O=CN[C@H](C(=O)O)CC1=CC=CC=C1 NSTPXGARCQOSAU-VIFPVBQESA-N 0.000 claims 1
- 208000007256 Nevus Diseases 0.000 claims 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 241000241413 Propolis Species 0.000 claims 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 206010000210 abortion Diseases 0.000 claims 1
- 231100000176 abortion Toxicity 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- BJQHLKABXJIVAM-UHFFFAOYSA-N bis(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 claims 1
- 230000005907 cancer growth Effects 0.000 claims 1
- 230000001276 controlling effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000002357 endometrial effect Effects 0.000 claims 1
- 230000004153 glucose metabolism Effects 0.000 claims 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- 239000008267 milk Substances 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 229960003104 ornithine Drugs 0.000 claims 1
- 210000004681 ovum Anatomy 0.000 claims 1
- 230000032696 parturition Effects 0.000 claims 1
- 230000003169 placental effect Effects 0.000 claims 1
- 239000003380 propellant Substances 0.000 claims 1
- 229940069949 propolis Drugs 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 102000013599 Kisspeptins Human genes 0.000 abstract 1
- 108010012048 Kisspeptins Proteins 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 230000000994 depressogenic effect Effects 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Abstract
DC60 (20/03/50) การประดิษฐ์ให้อนุพันธ์เมทาสทินที่เสถียรที่มีแอคทิวิทีทางชีววิทยาที่ดีเยี่ยม (แอคทิวิทีกด การแพร่กระจายของมะเร็ง, แอคทิวิทีกดการเจริญของมะเร็ง, แอคทิวิทีกระตุ้นการหลั่งฮอร์โมนจาก ต่อมบ่งเพศ, แอคทิวิทีกระตุ้นการหลั่งฮอร์โมนเพศ, และอื่น ๆ) โดยการแทนที่อะมิโน แอซิดที่เป็นส่วนประกอบของเมทาสทินด้วยอะมิโน แอซิดจำเพาะใน อนุพันธ์เมทาสทินของการประดิษฐ์, เสถียรภาพในเลือด, สภาพละลายได้, และอื่น ๆ ถูกปรับปรุงให้ดี มากขึ้น, แนวโน้มการก่อเจลถูกทำให้ลดลง, เภสัชจลนศาสตร์ยังถูกปรับปรุงให้ดีขึ้น, และแอคทิวทีกด การแพร่กระจายของมะเร็งหรือแอคทิวิทีกดการเจริญของมะเร็งที่ดีเยี่ยมถูกแสดง นอกจากนี้, อนุพันธ์ เมทาสทินของการประดิษฐ์มีผลกดการหลั่งฮอร์โมนจากต่อมบ่งเพศ, กดการหลั่งฮอร์โมนเพศ, และ อื่น ๆ สิทธิบัตรยา
Claims (1)
1. วิธีสำหรับป้องกันมะเร็งที่พึ่งพิงฮอร์โมน, ซึ่งประกอบรวมด้วยการให้แก่สัตว์เลี้ยง ลูกด้วยนมขนาดยาที่ให้ผลของอนุพันธ์เมทาสทินตามข้อถือสิทธิข้อ 1 ถึง 19 ข้อใดข้อหนึ่ง,หรือ เกลือของสารเหล่านั้น,หรือโพรดรักของสารเหล่านั้น
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TH95342A TH95342A (th) | 2009-04-30 |
| TH71270B true TH71270B (th) | 2019-08-28 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vigneaud et al. | The synthesis of an octapeptide amide with the hormonal activity of oxytocin | |
| KR101226165B1 (ko) | 피부 외용제 조성물 | |
| Vanderah et al. | FE200041 (D-Phe-D-Phe-D-Nle-D-Arg-NH2): A peripheral efficacious κ opioid agonist with unprecedented selectivity | |
| SI8011553A8 (sl) | Postopek za pripravo nonapeptidnih in dekapeptidnih derivatov hormonov za sproščanje luteinizirajočega hormona | |
| JP5449673B2 (ja) | 対象者におけるメラニン形成を誘導するための組成物および方法 | |
| HUE026644T2 (en) | A mixture for transdermal delivery of low and high molecular weight compounds | |
| TWI882141B (zh) | 用於修復黏膜損傷或皮膚創傷的多肽及其應用 | |
| AU2011201914A1 (en) | Adrenocorticotropic hormone analogs and related methods | |
| HUP0003592A2 (hu) | LH-RH peptid analógok, alkalmazásuk, és ezeket tartalmazó gyógyászati készítmények | |
| JP2021534134A (ja) | 皮膚、毛髪、爪および／または粘膜の処置および／またはケアに有用な化合物 | |
| CN1879888B (zh) | 透皮给药增强剂及其使用方法 | |
| DE60207043T2 (de) | Histidin-reiches glykoprotein (hrgp) zur inhibierung der angiogenese | |
| AU2023233094A1 (en) | Anti-inflammatory agents | |
| Montagnani Marelli et al. | Oxime bond-linked daunorubicin-GnRH-III bioconjugates exert antitumor activity in castration-resistant prostate cancer cells via the type I GnRH receptor | |
| CA2540539A1 (en) | A mixture for transdermal delivery of low and high molecular weight compounds comprising an ethoxylated oil | |
| NZ282876A (en) | Use of mcp-1 for inducing ripening of the cervix | |
| CN101848927A (zh) | 镇痛化合物 | |
| TH71270B (th) | อนุพันธ์เมทาสทินและการใช้ของสารเหล่านั้น | |
| TH95342A (th) | อนุพันธ์เมทาสทินและการใช้ของสารเหล่านั้น | |
| WO2018171535A1 (zh) | 重组人胰岛素原融合蛋白及其制备方法和用途 | |
| CA2500897A1 (en) | Long-acting gonadotropin-releasing hormone analogs and methods of use thereof | |
| US20060100154A1 (en) | Long-acting gonadotropin-releasing hormone analogs and methods of use thereof | |
| US8945575B2 (en) | Treatment of IgE-mediated disease | |
| EP1909814B1 (en) | Peptides for induction and enhancement of apoptosis in tumor cells | |
| Callery et al. | The effects of a low therapeutic dose of βCG fragment–lytic peptide conjugates on ovarian function and gonadotropin secretion in ewes: A randomized controlled trial |